{"id":62060,"date":"2025-10-21T07:02:50","date_gmt":"2025-10-21T05:02:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/"},"modified":"2025-10-21T07:02:50","modified_gmt":"2025-10-21T05:02:50","slug":"auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/","title":{"rendered":"Auna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029"},"content":{"rendered":"
\n

\n(CUSIP NOS. 05151A AA1 \/ L0415A AA1)<\/p>\n

LUXEMBOURG–(BUSINESS WIRE)–Auna S.A. (NYSE: AUNA), a public limited liability company (soci\u00e9t\u00e9 anonyme<\/i>) incorporated and existing under the laws of Luxembourg, having its registered office at 6, rue Jean Monnet, L-2180 Luxembourg, and registered with the Luxembourg Trade and Companies Register (Registre de Commerce et des Soci\u00e9t\u00e9s, Luxembourg<\/i>) under number B267590 (\u201cAuna\u201d or the \u201cCompany\u201d), a Latin American healthcare company with operations in Mexico, Peru and Colombia, announced today the commencement of an offer to purchase for cash of any and all of the outstanding 10.000% Senior Notes due 2029 issued by Auna (the \u201cNotes\u201d), upon the terms and subject to the conditions set forth in the Offer to Purchase and Consent Solicitation Statement dated October 20, 2025 (the \u201cOffer to Purchase\u201d) for the consideration described below (the \u201cTender Offer\u201d). All capitalized terms used herein but not defined in this announcement have the respective meanings ascribed to them in the Offer to Purchase.<\/p>\n

<\/a>
<\/a><\/p>\n

\nSimultaneously with the Tender Offer, we are conducting a solicitation of consents (the \u201cConsent Solicitation\u201d) from Holders of the Notes to effect certain proposed amendments to the indenture governing the Notes dated as of December 18, 2023 (as amended and supplemented from time to time, the \u201cBase Indenture\u201d), by and among the Company, the guarantors party thereto (the \u201cGuarantors\u201d) and Citibank, N.A., as trustee, paying agent, registrar and transfer agent (the \u201cTrustee\u201d), under which the Notes were issued, as amended and supplemented by a first supplemental indenture dated October 18, 2024 by and among, the Company, the Guarantors and the Trustee (the \u201cFirst Supplemental Indenture\u201d and together with the Base Indenture, the \u201cIndenture\u201d). The Proposed Amendments (as defined below) with respect to the Indenture would eliminate substantially all of the restrictive covenants as well as certain events of default and related provisions contained therein, as further described in the Offer to Purchase (the \u201cProposed Amendments\u201d). Pursuant to the terms of such Indenture, the Proposed Amendments require the consents of Holders of at least a majority in aggregate principal amount of the Notes outstanding (excluding any Notes held by the Company or its affiliates) (the \u201cRequisite Consents\u201d). The term \u201cHolder\u201d means a registered holder of Notes.<\/p>\n

\nHolders that tender their Notes pursuant to the Tender Offer and in accordance with the procedures described in this Offer to Purchase will be deemed to have delivered their consent to the Proposed Amendments pursuant to the Consent Solicitation. Holders may not deliver consents to the Proposed Amendments without tendering the related Notes. If a Holder tenders Notes in the Tender Offer, such Holder will be deemed to deliver its consent, with respect to the principal amount of such tendered Notes, to the Proposed Amendments.<\/p>\n

\nThe following table summarizes certain payment terms of the Tender Offer and Consent Solicitation:<\/p>\n\n\n\n
\n

\nTitle of Security<\/b><\/p>\n<\/td>\n

\n

\nISIN\/CUSIP Numbers<\/b><\/p>\n<\/td>\n

\n

\nPrincipal Outstanding Amount<\/b><\/p>\n<\/td>\n

\n

\nTender Offer Consideration(1)<\/sup><\/b><\/p>\n<\/td>\n

\n

\nEarly Tender Payment(1)(2)<\/sup><\/b><\/p>\n<\/td>\n

\n

\nTotal Consideration(1)<\/sup><\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\n10.000% Senior Secured Notes due 2029<\/p>\n<\/td>\n

\n

\nUS05151AAA16\/
\n
USL0415AAA18<\/p>\n

\n05151A AA1 \/
\n
L0415A AA1<\/p>\n<\/td>\n

\n

\nU.S.$372,937,161<\/p>\n<\/td>\n

\n

\nU.S.$1,020<\/p>\n<\/td>\n

\n

\nU.S.$50<\/p>\n<\/td>\n

\n

\nU.S.$1,070<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n
\n

\n(1)<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nThe amount to be paid for each U.S.$1,000 principal amount of Notes validly tendered (and not validly withdrawn) and accepted for purchase, excluding Accrued Interest (as defined herein).<\/p>\n<\/td>\n<\/tr>\n

\n

\n(2)<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nIncremental amount to be paid in addition to the Tender Offer Consideration (which is included in the Total Consideration), only applicable to Holders that validly tender and do not validly withdraw their Notes at or prior to the Early Tender Date.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nThe Tender Offer will expire at 5:00 p.m., New York City time, on November 18, 2025, unless extended or earlier terminated by the Company (such time and date, as it may be extended or earlier terminated with respect to the Tender Offer and related Consent Solicitation, the \u201cExpiration Date\u201d). Holders who validly tender (and do not validly withdraw) their Notes and deliver (and do not revoke) their related consents to the Proposed Amendments at or prior to 5:00 p.m., New York City time, October 31, 2025, unless extended by the Company (such time and date, as the same may be extended, the \u201cEarly Tender Date\u201d), in the manner described in the Offer to Purchase will be eligible to receive the Total Consideration, which includes the Early Tender Payment with respect to the Notes, plus any Accrued Interest. Notes tendered may be withdrawn and consents delivered may be revoked at any time at or prior to 5:00 p.m., New York City time, October 31, 2025, unless extended by the Company (such time and date, as the same may be extended, the \u201cWithdrawal Deadline\u201d), but not thereafter, except as may be required by applicable law.<\/p>\n

\nTo be eligible to receive the Total Consideration set forth in the table above, Holders must validly tender and not validly withdraw their Notes at or prior to the Early Tender Date. Holders who do not validly tender their Notes at or prior to the Early Tender Date will not be paid the Early Tender Payment and will only be eligible to receive the Tender Offer Consideration. <\/b>All Holders who validly tender their Notes will also receive accrued and unpaid interest on the Notes from the last interest payment date on the Notes preceding the applicable Settlement Date to, but excluding, such Settlement Date (as defined herein). In addition, in the event of a termination of the Tender Offer and Consent Solicitation, none of the Total Consideration, the Tender Offer Consideration or any Accrued Interest will be paid or become payable to the Holder of such Notes, and the Notes tendered pursuant to the Tender Offer will be promptly returned to the tendering Holders.<\/p>\n

\nAt the Company\u2019s option, payment for Notes validly tendered at or prior to the Early Tender Date and accepted for purchase will be made on the early settlement date, expected to be within four business days following the Early Tender Date, or November 6, 2025, or as promptly as practicable thereafter (the \u201cEarly Settlement Date\u201d).<\/p>\n

\nIf the Early Settlement Date occurs with respect to the Notes, payment for Notes validly tendered after the Early Tender Date and at or prior to the Expiration Date and accepted for purchase will be made on the final settlement date, expected to be within three business days following the Expiration Date, or November 21, 2025, or as promptly as practicable thereafter (the \u201cFinal Settlement Date\u201d). The Notes validly tendered after the Early Tender Date but at or prior to the Expiration Date and so accepted will receive the Tender Offer Consideration, plus any Accrued Interest, on the Final Settlement Date, but not the Early Tender Payment. If no Early Settlement Date occurs, then payment for all the Notes that are validly tendered and not validly withdrawn at any time prior to the Expiration Time and that are accepted for purchase will be made on the Final Settlement Date.<\/p>\n

\nAuna\u2019s obligation to purchase Notes pursuant to the Tender Offer is subject to the satisfaction or waiver of certain conditions described in the Offer to Purchase and Consent Solicitation Statement under \u201cThe Tender Offer and Consent Solicitation\u2014Conditions to the Tender Offer and Solicitation,\u201d which include, (i) the receipt of the Requisite Consents and (ii) the successful consummation of a Proposed New Notes Offering and a Proposed Term Loan (each as defined in the Offer to Purchase).<\/p>\n

\nAuna reserves the right, in its sole discretion, (1) to waive any and all conditions to the Tender Offer or Consent Solicitation; (2) to extend the Tender Offer or Consent Solicitation; and (3) to terminate or to otherwise amend the Tender Offer or Consent Solicitation in any respect.<\/p>\n

\nAt any time after the Withdrawal Deadline and before the Expiration Date, if we have received the Requisite Consents, on such date, we, each of the Guarantors of the Notes and the Trustee may execute and deliver a second supplemental indenture to the Indenture, which will give effect to the Proposed Amendments to the Notes.<\/p>\n

\nNeither the Offer to Purchase nor any related documents have been filed with or reviewed by any federal or state securities commission or regulatory authority of any country. No authority has passed upon the accuracy or adequacy of the Offer to Purchase or any related documents, and it is unlawful and may be a criminal offense to make any representation to the contrary.<\/p>\n

\nThe Tender and Information Agent for the Tender Offer and Consent Solicitation is Global Bondholder Services Corporation. Additional contact information of the Tender and Information Agent is set forth below.<\/p>\n

\nGlobal Bondholder Services Corporation<\/b><\/p>\n\n\n
\n

\nAttn: Corporate Actions
\n
65 Broadway \u2013 Suite 404
\n
New York, NY 10006<\/p>\n

\nBanks and Brokers call: +1 (212) 430-3774
\n
All others call toll-free: +1 (855) 654-2014
\n
E-mail: contact@gbsc-usa.com<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAny questions or requests for assistance or for copies of the Offer to Purchase may be directed to the Tender and Information Agent at one of its telephone numbers above. A Holder (or a beneficial owner that is not a Holder) may also contact the Dealer Managers and Solicitation Agents at their telephone numbers set forth below or its broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Tender Offer and Consent Solicitation.<\/p>\n\n\n
\n

\nCitigroup Global Markets Inc.<\/p>\n

<\/b><\/p>\n

\n388 Greenwich Street, Trading 4th Floor<\/p>\n

\nNew York, New York 10013<\/p>\n

\nUnited States of America<\/p>\n

\nAttn: Liability Management Group<\/p>\n

\nCollect: +1 (212) 723-6106<\/p>\n

\nToll-Free: +1 (800) 558-3745<\/p>\n

\nEmail: Ny.liabilitymanagement@citi.com<\/a><\/p>\n<\/td>\n

\n

\nHSBC Securities (USA) Inc.<\/b><\/p>\n

\n\u00a0<\/p>\n

\n66 Hudson Boulevard<\/p>\n

\nNew York, NY<\/p>\n

\n10001<\/p>\n

\nAttn: Global Liability Management Group<\/p>\n

\nToll-Free: +1 (888) HSBC-4LM<\/p>\n

\nCall Collect: +1(212) 525- 5552<\/p>\n

\nE-mail: lmamericas@us.hsbc.com<\/a><\/p>\n<\/td>\n

\n

\nSantander US Capital Markets LLC
\n
<\/b><\/p>\n

\n437 Madison Avenue<\/p>\n

\nNew York, New York 10022<\/p>\n

\nUnited States of America<\/p>\n

\nAttn: Liability Management Group<\/p>\n

\nToll Free: +1 (855) 404-3636<\/p>\n

\nCollect: +1 (212) 940-1442<\/p>\n

\nE-Mail: AmericasLM@santander.us<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nThis notice does not constitute or form part of any offer or invitation to purchase, or any solicitation of any offer to sell, the Notes or any other securities in the United States or any other country, nor shall it or any part of it, or the fact of its release, form the basis of, or be relied on or in connection with, any contract therefor. The Tender Offer and Solicitation are made only by and pursuant to the terms of the Offer to Purchase and Consent Solicitation Statement, and the information in this notice is qualified by reference to the Offer to Purchase and Consent Solicitation Statement. None of Auna, the Guarantors, the Dealer Managers and Solicitation Agents or the Tender and Information Agent makes any recommendation as to whether Holders should tender their Notes pursuant to the Tender Offer and Solicitation.<\/p>\n

\nThis notice is not an offer to sell or a solicitation of an offer to buy New Notes (as defined in the Offer to Purchase). Tendering Holders who wish to tender their Notes for cash and also subscribe for New Notes should quote a unique identifier code corresponding to the New Notes being subscribed (\u201cUnique Identifier Code\u201d), which can be obtained by contacting the Dealer Managers and Solicitation Agents. The receipt of a Unique Identifier Code in conjunction with any tender of Notes in the Tender Offer is not an allocation of the New Notes. In order to apply for the purchase of the New Notes, such tendering Holders must make a separate application in respect of the New Notes for the purchase of such New Notes. If the Proposed New Notes Offering is announced, the Company will review tender instructions received on or prior to the pricing of the New Notes, and may give priority to those investors tendering with Unique Identifier Codes in connection with the allocation of New Notes. However, no assurances can be given that any Holder that tenders its Notes will be given an allocation of New Notes at the levels it may subscribe for, or at all.<\/p>\n

\nAbout Auna<\/b><\/p>\n

\nAuna is one of Latin America\u2019s leading healthcare platforms, with operations in Mexico, Peru, and Colombia. It prioritizes prevention and focuses on complex diseases that represent the highest healthcare spending. Its mission is to transform healthcare by delivering access to a highly integrated offering of services in low-penetration markets across Spanish-speaking Latin America.<\/p>\n

\nFounded in 1989, Auna has built one of the region\u2019s largest modern healthcare platforms, consisting of a horizontally integrated network of medical care centers and a vertically integrated portfolio of oncology and general health plans. As of June 30, 2025, Auna\u2019s network included 31 healthcare facilities\u2014hospitals, ambulatory centers, and prevention and wellness centers\u2014with a total of 2,323 beds and 1.4 million health plan members.<\/p>\n

\nCautionary Statement on Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often are proceeded by words such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201cmay,\u201d \u201canticipates,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cassumes,\u201d \u201cwill\u201d or similar expressions. The forward-looking statements contained herein include statements about the Company\u2019s Tender Offer and Consent Solicitation and potential new financings. These expectations may or may not be realized. Some of these expectations may be based upon assumptions or judgments that prove to be incorrect. In addition, Auna\u2019s business and operations involve numerous risks and uncertainties, many of which are beyond the control of Auna, which could result in Auna\u2019s expectations not being realized or otherwise materially affect the financial condition, results of operations and cash flows of Auna. Some of the factors that could cause future results to materially differ from recent results or those projected in forward-looking statements are described in Auna\u2019s filings with the United States Securities and Exchange Commission, including its annual report filed on Form 20-F on April 10, 2025.<\/p>\n

\nThe forward-looking statements are made only as of the date hereof, and Auna does not undertake any obligation to (and expressly disclaims any obligation to) update any forward-looking statements to reflect events or circumstances after the date such statements were made, or to reflect the occurrence of unanticipated events. In light of the risks and uncertainties described above, and the potential for variation of actual results from the assumptions on which certain of such forward-looking statements are based, investors should keep in mind that the results, events or developments disclosed in any forward-looking statement made in this document may not occur, and that actual results may vary materially from those described herein, including those described as anticipated, expected, targeted, projected or otherwise.<\/p>\n

Contacts<\/b> <\/p>\n

\ncontact@aunainvestors.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

(CUSIP NOS. 05151A AA1 \/ L0415A AA1) LUXEMBOURG–(BUSINESS WIRE)–Auna S.A. (NYSE: AUNA), a public limited liability company (soci\u00e9t\u00e9 anonyme) incorporated and existing under the laws of Luxembourg, having its registered office at 6, rue Jean Monnet, L-2180 Luxembourg, and registered with the Luxembourg Trade and Companies Register (Registre de Commerce et des Soci\u00e9t\u00e9s, Luxembourg) under … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62060","6":"format-standard","7":"category-industry"},"yoast_head":"\nAuna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Auna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"(CUSIP NOS. 05151A AA1 \/ L0415A AA1) LUXEMBOURG–(BUSINESS WIRE)–Auna S.A. (NYSE: AUNA), a public limited liability company (soci\u00e9t\u00e9 anonyme) incorporated and existing under the laws of Luxembourg, having its registered office at 6, rue Jean Monnet, L-2180 Luxembourg, and registered with the Luxembourg Trade and Companies Register (Registre de Commerce et des Soci\u00e9t\u00e9s, Luxembourg) under ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T05:02:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251020174029\/en\/2522769\/22\/Auna_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Auna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029\",\"datePublished\":\"2025-10-21T05:02:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/\"},\"wordCount\":2368,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020174029\\\/en\\\/2522769\\\/22\\\/Auna_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/\",\"name\":\"Auna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020174029\\\/en\\\/2522769\\\/22\\\/Auna_logo.jpg\",\"datePublished\":\"2025-10-21T05:02:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020174029\\\/en\\\/2522769\\\/22\\\/Auna_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251020174029\\\/en\\\/2522769\\\/22\\\/Auna_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Auna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Auna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/","og_locale":"en_US","og_type":"article","og_title":"Auna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029 - Pharma Trend","og_description":"(CUSIP NOS. 05151A AA1 \/ L0415A AA1) LUXEMBOURG–(BUSINESS WIRE)–Auna S.A. (NYSE: AUNA), a public limited liability company (soci\u00e9t\u00e9 anonyme) incorporated and existing under the laws of Luxembourg, having its registered office at 6, rue Jean Monnet, L-2180 Luxembourg, and registered with the Luxembourg Trade and Companies Register (Registre de Commerce et des Soci\u00e9t\u00e9s, Luxembourg) under ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-21T05:02:50+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251020174029\/en\/2522769\/22\/Auna_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Auna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029","datePublished":"2025-10-21T05:02:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/"},"wordCount":2368,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251020174029\/en\/2522769\/22\/Auna_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/","url":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/","name":"Auna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251020174029\/en\/2522769\/22\/Auna_logo.jpg","datePublished":"2025-10-21T05:02:50+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251020174029\/en\/2522769\/22\/Auna_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251020174029\/en\/2522769\/22\/Auna_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/auna-s-a-announces-commencement-of-cash-tender-offer-and-consent-solicitation-of-any-and-all-of-its-outstanding-10-000-senior-secured-notes-due-2029\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Auna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62060"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62060\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}